Evidence-Based Medications for Androgenetic Alopecia (AGA):
The two primary evidence-based pharmacological treatments for androgenetic alopecia are topical minoxidil and oral finasteride, both FDA-approved and supported by UK guidelines NICE CKS,NICE CKS Lai et al. 2026.
Topical Minoxidil: Minoxidil, applied topically in concentrations typically of 2% or 5%, acts by stimulating hair growth primarily through vasodilation, increasing hair follicle blood supply, enhancing and prolonging the anagen phase, and stimulating follicular recovery from telogen phase SmPC Regaine,SmPC Regaine,NICE CKS,NICE CKS Lai et al. 2026. The UK NICE CKS recommends topical minoxidil for both male and female pattern hair loss NICE CKS,NICE CKS. Clinical trials demonstrate statistically significant hair count increases with 5% minoxidil foam compared to vehicle, with improvements evident as early as 8 weeks and persisting at 16 weeks SmPC Regaine. Topical minoxidil is generally well tolerated but can cause local irritation or contact dermatitis and requires continuous use to maintain effects SmPC Regaine Lai et al. 2026.
Oral Finasteride: Finasteride is a selective inhibitor of type II 5α-reductase, blocking conversion of testosterone to dihydrotestosterone (DHT), a major androgen involved in hair follicle miniaturization SmPC Finasteride,NICE CKS Lai et al. 2026. Oral finasteride 1 mg daily is recommended primarily for men with male pattern hair loss NICE CKS. Clinical studies show significant improvement in hair count and hair growth assessments after 2 years, with stabilization or moderate improvement maintained at 5 years SmPC Finasteride. The medication is contraindicated in women, particularly those who are or may become pregnant, due to potential teratogenicity SmPC Finasteride,NICE CKS. Potential adverse effects include sexual dysfunction and mood changes; patient selection and monitoring are important Lai et al. 2026.
Combination Therapy: Combining topical minoxidil with finasteride has demonstrated superior efficacy over monotherapy, reflecting complementary mechanisms—minoxidil stimulates follicular growth, while finasteride suppresses the androgenic driver NICE CKS,NICE CKS,SmPC Finasteride,SmPC Regaine Lai et al. 2026. Meta-analyses and controlled trials report higher hair density, improved hair diameter, and better global photographic assessment with combination therapy, without significant increase in adverse effects PubMed Lai et al. 2026. Lower doses in combination also help reduce side effects, enhancing patient adherence.
Other Antiandrogens — Spironolactone: Particularly used in female pattern hair loss, spironolactone acts via androgen receptor antagonism, reducing androgen action on follicles PubMed. While not licensed in the UK specifically for AGA, evidence supports its use in women, often in combination with minoxidil, to improve hair density, with generally mild and manageable side effects PubMed Lai et al. 2026. Its use in men is limited due to risk of feminizing adverse effects.
Emerging and Adjunctive Therapies: Beyond these mainstays, recent advances in biomedical technology incorporating nanocarrier systems, microneedle drug delivery, and regenerative modalities such as platelet-rich plasma (PRP) and stem cell–derived exosomes have shown promise for AGA, though these remain investigational or adjunctive PubMed (Cao et al., N/A) Lai et al. 2026. These approaches aim to improve targeted delivery, enhance follicular microenvironment, and address inflammation, oxidative stress, and angiogenesis dysregulation inherent in AGA pathogenesis.
Summary: The cornerstone evidence-based medications for androgenetic alopecia in UK practice are topical minoxidil and oral finasteride, either alone or in combination for enhanced efficacy NICE CKS,NICE CKS,SmPC Finasteride,SmPC Regaine. Spironolactone is considered a useful alternative primarily in women NICE CKS,PubMed. Novel biomedical technologies and combination regimens offer exciting future directions but require further validation PubMed,PubMed. Patient selection, close monitoring for side effects, and counseling on adherence and realistic outcomes remain essential for optimizing treatment success NICE CKS,PubMed.
Key References
- NICE CKS: Male pattern hair loss (male androgenetic alopecia)
- NICE CKS: Female pattern hair loss (female androgenetic alopecia)
- SmPC: Finasteride 1 mg film-coated tablets
- SmPC: Regaine for Men Extra Strength Scalp Foam 5% w/w Cutaneous Foam (GSL)
- SmPC: Regaine for Men Extra Strength Scalp Solution 5% w/v Cutaneous Solution
- NICE CG97: Lower urinary tract symptoms in men: management
- NICE NG131: Prostate cancer: diagnosis and management
- (Blume-Peytavi and Vogt, 2013): [Androgenetic alopecia. Diagnosis and therapy- a current review].
- (Mirmirani, 2015): Age-related hair changes in men: mechanisms and management of alopecia and graying.
- (Kaufman et al., 2025): Cancer-Related Alopecia Risk and Treatment.
- (Lai et al., 2026): Advances in the Treatment of Androgenetic Alopecia: A Review of Mechanisms and the Clinical Efficacy of Combination Drug Therapy
- (Cao et al., N/A): Biomedical Technologies for Androgenic Alopecia Treatment: Advance, Mechanism and Future Direction
- (Kapoor et al., 2026): Precision therapeutics in non-scarring alopecia: a systemic genomic and pathway-based framework for targeted interventions.